Dunakeszi, Hungary

Attila Vasas



Average Co-Inventor Count = 9.6

ph-index = 1


Company Filing History:


Years Active: 2015-2016

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Profile: Attila Vasas

Introduction

Attila Vasas is a notable inventor hailing from Dunakeszi, Hungary. With a strong focus on innovative solutions in the pharmaceutical sector, he has contributed to the development of critical compounds that target specific diseases.

Latest Patents

Attila Vasas holds two significant patents, both related to CXCR3 receptor antagonists. The details of his latest inventions are as follows:

1. **Substituted B-amino acid derivatives as CXCR3 receptor antagonists** - This invention pertains to compounds useful for the preventive and therapeutic treatment of diseases associated with the abnormal activation of CXCR3 chemokines. It also covers the processes for preparing these compounds, pharmaceutical compositions containing them, and novel intermediates used in their preparation.

2. **Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists** - Similar in focus, this invention relates to compounds that serve as potential treatments for diseases caused by the abnormal activation of CXCR3 chemokines. It includes details on the preparation processes, pharmaceutical compositions, and intermediates involved.

Career Highlights

Attila is actively employed at Sanofi, a leading global healthcare company. His work at Sanofi underscores his commitment to advancing medical science through innovative research and development.

Collaborations

Throughout his career, Attila has collaborated with talented individuals such as Imre Bata and Veronika Bartane Bodor. These collaborations highlight the importance of teamwork in driving innovative solutions within the pharmaceutical industry.

Conclusion

In summary, Attila Vasas is a distinguished inventor whose contributions to the field of pharmaceuticals are marked by his impressive patents and collaborative efforts. His work continues to pave the way for potential therapeutic advancements that could greatly benefit those affected by diseases linked to CXCR3 chemokines.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…